Recruiting

Observational Study

Sponsor:

University of Kansas Medical Center

Code:

NCT06626113

Conditions

Obesity

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

ascorbic acid

Study Details

Brief summary:

In addition to chronically elevated MSNA, there is a growing recognition that hypertension in states of insulin resistance and obesity may also be attributed to an increased vascular sensitivity to MSNA (1, 2, 13, 36-38). To study this phenomenon, we quantify vascular sensitivity to MSNA using an innovative, moment-to-moment assessment of the blood pressure response following individual bursts of muscle sympathetic nerve activity (MSNA), (10, 11, 34, 37). This approach is termed 'sympathetic-vascular transduction (SVT).' We will examine the hypothesis that SVT is exaggerated in obesity and insulin resistance and is attenuated by suppression of oxidative stress. Oxidative stress is the overabundance of reactive oxygen species and is another hallmark of hypertension, obesity, and insulin resistance. Oxidative stress can be safely reduced via intravenous infusion of ascorbic acid (Vit C) (4, 28). Therefore, we will use a randomized, double-blinded, placebo-controlled approach to test the hypothesis that elevated SVT will be attenuated by suppression of oxidative stress via ascorbic acid I.V. infusion compared with saline I.V. infusion (placebo) in obese adults with insulin resistance. Our study will identify a unique mechanism that can be targeted to reduce the excessively high prevalence of hypertension and risk for CVD in obesity and insulin resistance.

Conditions

Obesity

Study ID

NCT06626113

Start date

Aug 1, 2022

Status verified date

Oct, 2024

Completion date

Sep 1, 2027

Anticipated

Primary completion date

Sep 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion criteria:

1. Obese: BMI >25 m/kg2
2. Elevated insulin resistance: HOMA-IR > 2.5 (calculation based on fasting glucose and insulin concentrations in blood)
3. Middle-aged: 35-65 years
4. Participants must be willing and able to discontinue taking any vitamin C or E supplements or omega-3 fatty acids beginning 2 weeks prior.
5. Able and willing to provide written informed consent

Exclusion criteria:

1. Currently taking a statin or antihypertension medication
2. Hyperlipidemia: Fasting triglycerides < 250 mg/dL
3. Hypertension: >130/80 mmHg
4. History of heart disease (e.g., myocardial infarction, stent)
5. History of vascular disease (e.g., bypass, stroke)
6. Individuals with narrow angle glaucoma

-

Study Design

Enrollment

60 participants

Anticipated

Interventions and Outcome Measures

Arms

Obese

Interventions

ascorbic acid

ascorbic acid

Primary outcome measure

  • Sympathetic transduction [ Time Frame: 2 hours ]

Central Contacts and Locations

Central contacts

Locations

University of Kansas Medical Center

Recruiting

Kansas City, Kansas, United States, 66160

More Information

Sponsor

University of Kansas Medical Center

Last update posted

Oct 3, 2024

Last verified

Oct, 2024

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Kansas Medical Center on 2024-10-03.